NVCR · NovoCure Ltd · Investor Relations

Third quarter net revenues of $193 million an increase of 16% year-over-year, driven by 19% growth in active patients worldwide Strong performance drove increased net revenue guidance for full-year 2026 to $736 million - $743 million and adjusted EBITDA guidance to $24 million - $34 million Optune

BAAR, Switzerland --(BUSINESS WIRE)--Oct. 28, 2026-- Novocure (Nasdaq: NVCR) announced today that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of Novocure’s Tumor Treating Fields (TTFields) therapy with chemotherapy and VS-7375,

BAAR, Switzerland --(BUSINESS WIRE)--Oct. 1, 2026-- Novocure (Nasdaq: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax ® for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, concomitant with

BAAR, Switzerland --(BUSINESS WIRE)--Oct. 1, 2026-- Novocure (Nasdaq: NVCR) will report financial results for the third quarter 2026 on October 29, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m.

BAAR, Switzerland --(BUSINESS WIRE)--Sep. 2, 2026-- Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. Wells Fargo 21st Annual Healthcare Conference, September 9, 2026: Frank Leonard, Chief Executive Officer, will take part in a fireside chat

Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications CE Mark received for Optune Pax® for the treatment of locally advanced pancreatic cancer, Germany first market to launch in EU More than 280 active patients on

BAAR, Switzerland --(BUSINESS WIRE)--Jul. 1, 2026-- Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m.

The CE Mark is supported by results from the Phase 3 PANOVA-3 trial demonstrating a statistically significant improvement in overall survival (OS) for patients treated with Optune Pax concomitant with gemcitabine and nab-paclitaxel Treatment with Optune Pax was also shown to significantly delay

The Phase 3 TRIDENT trial enrolled patients with glioblastoma prior to the initiation of chemoradiation and evaluated the benefit of initiating Tumor Treating Fields (TTFields) therapy at the start of chemoradiation compared to initiating TTFields therapy in the maintenance phase TRIDENT did not

Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio® Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic cancer; more than 800 prescribers certified and more than 160 prescriptions received through March

BAAR, Switzerland --(BUSINESS WIRE)--Apr. 1, 2026-- Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m.

BAAR, Switzerland --(BUSINESS WIRE)--Mar. 26, 2026-- Novocure (NASDAQ: NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq ®), gemcitabine and nab-paclitaxel (gem/nab-pac) as a first-line

Novocure to launch Optune Lua in Japan with national reimbursement coverage BAAR, Switzerland --(BUSINESS WIRE)--Mar. 2, 2026-- Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua ® through the country’s National Health

BAAR, Switzerland --(BUSINESS WIRE)--Feb. 27, 2026-- Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 10, 2026. Frank Leonard, Chief Executive Officer, and Christoph Brackmann, Chief Financial Officer, will take